The present invention relates to a dental topical anesthetic gel containing a full spectrum blend of active cannabinoids and at least one component including tetracaine, benzocaine, lidocaine, and butamben. Further, the dental topical gel may also contain a chemical penetration enhancer, at least one drug to enhance the effects of cannabinoids, at least one antibacterial agent and at least one antifungal agent. The forms and use of the dental topical anesthetic gel are also disclosed.

The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

A pharmaceutical composition can include a lipophilic oil. The pharmaceutical composition can further include an analgesic agent, anesthetic agent, anti-inflammatory agent, or a mixture thereof dispersed in the lipophilic oil. The pharmaceutical composition can further include a structuring agent at least a portion of which is not dissolved in the lipophilic oil and forms a gel.

A pharmaceutical composition can include a lipophilic oil. The pharmaceutical composition can further include an analgesic agent, anesthetic agent, anti-inflammatory agent, or a mixture thereof dispersed in the lipophilic oil. The pharmaceutical composition can further include a structuring agent at least a portion of which is not dissolved in the lipophilic oil and forms a gel.

The present invention provides compositions useful in reducing or preventing pain in a subject in need thereof. In one embodiment, the compositions comprise a halogenated volatile compound. The present invention further includes a method of reducing or preventing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of the invention. Dosing regimens contemplated within the invention include one-time administration, continuous administration or periodic administration.

In some embodiments provided herein is a method of treating pain, the method comprising injecting into the subarachnoid space of the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

In some embodiments provided herein is a method of treating pain, the method comprising injecting into the subarachnoid space of the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

Described herein are compositions comprising an effective amount of a local anesthetic agent for blocking neural transmission at the superficial inguinal ring or canal, for treatment of symphysiolysis. The compositions may be for administration through the subcutaneous or transdermal route, preferably to a region between the symphysis pubis and the anterior superior iliac spine. Methods for treatment of symphysiolysis are also described.

Described herein are compositions comprising an effective amount of a local anesthetic agent for blocking neural transmission at the superficial inguinal ring or canal, for treatment of symphysiolysis. The compositions may be for administration through the subcutaneous or transdermal route, preferably to a region between the symphysis pubis and the anterior superior iliac spine. Methods for treatment of symphysiolysis are also described.

The disclosure is directed to fibrous structures finished with active pharmaceutical ingredients, as well as methods of their manufacturer and use.